A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti−PD-L1 Antibody) in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Patients With HER2-Positive Breast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer

Trial Profile

A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti−PD-L1 Antibody) in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Patients With HER2-Positive Breast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Pertuzumab; Trastuzumab; Trastuzumab emtansine
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 16 May 2017 Planned number of patients changed from 100 to 98.
    • 09 Mar 2017 Two new drugs doxorubicin and cyclophosphamide has been added in the study . Treatment arms has been changed from 5 to 10.
    • 09 Mar 2017 Planned number of patients changed from 66 to 100.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top